Orexo's Q3 2024 Financial Highlights
During the third quarter of 2024, Orexo faced several challenges that impacted their financial results. The company reported total net revenues of SEK 136.5 million, a decrease from SEK 156.1 million in the previous year. This decline was accompanied by an EBITDA loss of SEK -0.7 million, an improvement over last year’s loss of SEK -9.5 million, but still reflecting ongoing operational challenges.
Key Financial Metrics
In addition to revenue figures, Orexo reported a net earnings loss of SEK -41.9 million compared to -33.3 million from the previous year. The US commercial segment net revenues were recorded at SEK 131.0 million, which translates to local currency figures of approximately USD 12.6 million. Moreover, cash flow from operating activities yielded SEK -13.4 million, showing a reduced cash need compared to the previous year.
Sustainability and Regulatory Update
Orexo’s sustainability efforts have also gained recognition, ranking in the top five percent out of 70,000 businesses assessed by EcoVadis. This achievement reflects Orexo's commitment to corporate social responsibility and environment-friendly practices.
On regulatory matters, the company received a complete response letter from the FDA regarding OX124. This high-dose naloxone rescue medication is intended for opioid overdose treatment. The FDA requested additional technical data and further insights from a new human factors study, which Orexo successfully conducted earlier this year.
Looking Ahead: Guidance for 2024
Orexo reaffirmed its financial guidance for 2024 despite the results from the third quarter. The company remains optimistic about the approval of OX124 and aims to enhance its portfolio of treatment options for patients dealing with opioid use disorders. Furthermore, Orexo is seeing consistent demand for its existing product Zubsolv, indicating a steady market presence.
Upcoming Initiatives and Clinical Trials
In an important development post-Q3, Orexo initiated a phase 1 clinical study for OX640 targeting participants with allergic rhinitis. This exploratory step represents Orexo's commitment to expanding its therapeutic offerings and tapping into new market areas.
CEO Insights
The CEO, Nikolaj Sørensen, remarked on the challenges posed in Q3, particularly due to legal costs and adjustments related to royalty payments for Abstral. Nonetheless, the successful reduction in overall expenses by 15% provided some relief amid these hurdles. Looking forward, he expressed confidence about Zubsolv's stable prescription volumes and their efforts to resolve ongoing legal disputes.
Contact Information
For further details regarding the quarterly report, interested investors may reach out to the following key contacts:
Nikolaj Sørensen, President and CEO; Fredrik Järrsten, EVP and CFO; and Lena Wange, IR & Communications Director. They are available at:
Telephone: +46 18 780 88 00; +1 855 982 7658.
Email: ir@orexo.com.
Frequently Asked Questions
What are the main financial results for Orexo in Q3 2024?
Orexo reported total net revenues of SEK 136.5 million and an EBITDA loss of SEK -0.7 million for Q3 2024.
How did Orexo perform in the US market?
The US commercial segment net revenues were SEK 131.0 million, equivalent to around USD 12.6 million, demonstrating stable performance amidst challenges.
What has been said about Orexo's sustainability efforts?
Orexo ranked among the top five percent of firms assessed globally by EcoVadis, highlighting its commitment to sustainability.
What is the outlook for Orexo regarding OX124?
Orexo remains optimistic about receiving FDA approval for OX124, facilitating better treatment options for opioid overdose cases.
Who can I contact for more information about Orexo's quarterly report?
Investors can contact Nikolaj Sørensen, CEO, or Fredrik Järrsten, CFO, via phone or the provided email address for inquiries.
